Genmab A/SGMABNASDAQ
Loading
Net Income Growth Recovery in ProgressRecovering
Percentile Rank36
Studio
Year-over-Year Change

Year-over-year net income growth rate

Percentile
P36
Within normal range
vs 5Y Ago
-5.3x
Contraction
Streak
1 qtr
Consecutive growthRecovering
PeriodValue
Q4 2025-50.88%
Q3 2025-81.17%
Q2 2025991.92%
Q1 2025-94.93%
Q4 2024203.71%
Q3 2024523.65%
Q2 20245.73%
Q1 2024-70.00%
Q4 2023-69.58%
Q3 202357.60%
Q2 2023535.71%
Q1 2023-59.14%
Q4 2022-80.09%
Q3 202236.54%
Q2 2022306.67%
Q1 2022-35.06%
Q4 2021-19.55%
Q3 2021190.85%
Q2 2021-72.08%
Q1 202188.64%
Q4 20209.62%
Q3 2020-84.31%
Q2 20201155.76%
Q1 2020-81.72%
Q4 2019174.09%
Q3 2019531.76%
Q2 201918.06%
Q1 2019-91.37%
Q4 2018365.39%
Q3 2018-31.23%
Q2 201831.20%
Q1 2018-74.73%
Q4 201713933.27%
Q3 2017-101.85%
Q2 20171808.60%
Q1 2017-98.09%
Q4 2016345.29%
Q3 201612.32%
Q2 20161559.70%
Q1 2016-102.96%